Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22491496 | 0.92 | FNTA (0.47) | DRD2DRD4HTR2AHTR2CHTR2B | |
| SCHEMBL22773207 | 0.82 | GRM5 (0.42) | OPRD1OPRM1KCNH2GRM5 | |
| SCHEMBL22491472 | 0.82 | OPRM1 (0.42) | DRD2DRD4HTR2AHTR2CHTR2B | |
| SCHEMBL22491530 | 0.77 | HTR1F (0.42) | DRD2DRD4HTR2AHTR2CHTR2B | |
| SCHEMBL22491470 | 0.77 | MEN1 (0.44) | FNTAFNTBGRM5 | |
| SCHEMBL22491486 | 0.76 | OPRD1 (0.52) | DRD2DRD4HTR2AHTR2CHTR2B | |
| SCHEMBL22491406 | 0.70 | OPRD1 (0.49) | DRD2DRD4HTR2AHTR2CHTR2B | |
| SCHEMBL27152941 | 0.70 | HSD11B1 (0.39) | — | |
| SCHEMBL22491434 | 0.68 | FNTA (0.44) | DRD2DRD4HTR2AHTR2CHTR2B | |
| SCHEMBL5046191 | 0.68 | NPC1 (0.66) | P4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717477-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-07-20 | — | — | EP | disclosed |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-12-17 | — | — | US | disclosed |
| EP-3717477-A1 | NEW HETEROCYCLIC COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | LPXN, MLX, CCNY | DRD2 1811/4885DRD4 1290/4885HTR2A 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.